University of Maryland, Baltimore: Psychotic Disorders trials

The registry lists 24 Psychotic Disorders studies with University of Maryland, Baltimore as lead sponsor. 2 are open to participants now and 12 have results posted.

Phase 1 1Phase 2 4Phase 3 1Phase 4 5No phase 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With SchizophreniaNot yet recruitingNCT07615075Phase 4
• Targeting Emotion Dysregulation to Reduce Suicide in People With PsychosisRecruitingNCT05440214Not applicable
• TMS Related Biomarker AssessmentsCompletedNCT05660018Not applicableResults posted
• Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.CompletedNCT04325386Not applicableResults posted
• The Effects of Kynurenine Aminotransferase Inhibition in People With SchizophreniaCompletedNCT04013555Phase 1/2Results posted
• Prebiotic Treatment in People With Schizophrenia - Pilot StudyCompletedNCT03617783Phase 4Results posted
• Nicotinic Enhancement of Cognitive Remediation Training in SchizophreniaCompletedNCT02069392Not applicableResults posted
• The Family VOICE StudyCompletedNCT01804582Not applicableResults posted
• Oxytocin and CBSST for People With SchizophreniaCompletedNCT01752712Not applicableResults posted
• Biomarker Study of Acamprosate in SchizophreniaCompletedNCT00688324Phase 4Results posted
• The Effects of Rimonabant, on Weight and Metabolic Risk FactorsTerminatedNCT00547118Phase 2Results posted
• Varenicline Adjunctive Treatment in SchizophreniaCompletedNCT00492349Phase 4Results posted
• Clinical Trial of Dipyridamole in SchizophreniaCompletedNCT00349973Not applicableResults posted
• Efficacy Study of Galantamine for Cognitive Impairments in SchizophreniaCompletedNCT00176423Phase 4Results posted
• Ketogenic Diet in People With SchizophreniaTerminatedNCT05968638Not applicable
• Prebiotic Treatment in People With SchizophreniaActive, not recruitingNCT05527210Not applicable
• Luteolin for the Treatment of People With SchizophreniaCompletedNCT05204407Not applicable
• Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset PsychosisWithdrawnNCT03883360Phase 2
• Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)CompletedNCT03183609Not applicable
• Schizophrenia and the Gut MicrobiomeCompletedNCT02921243
• Neuroendocrine and Immune Response to Stress in SchizophreniaCompletedNCT01975584Not applicable
• Brain Circuits in Schizophrenia and SmokingCompletedNCT01425684
• Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease StatesCompletedNCT01425671
• Adjunctive Treatment for Decreasing Symptoms of SchizophreniaCompletedNCT00222235Phase 2/3